From 2014 to 2021, 14 out of 25 newly reimbursed treatments were tyrosine kinase inhibitors (TKIs) targeting tumors with epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) translocations and the proto-oncogene tyrosine-protein kinase (ROS-1), present in 1% to 11% of patients with advanced non-small cell lung carcinoma [14]. Here, ALK is linked to non-small cell lung carcinoma.